Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma.
Dimitrios C ZiogasPanagiotis DiamantopoulosOlga BenopoulouAmalia AnastasopoulouDimitrios BafaloukosAlexander J StratigosJohn M KirkwoodHelen GogasPublished in: The oncologist (2020)
The prognosis and management of pregnancy-associated melanoma whether BRAF-mutated or wild type, is currently guided by the same parameters as in the nonpregnant condition. In this special nontrial subpopulation, BRAF-mutated status seems to have a detrimental effect on disease outcome, independently of the following treatments. In early stage melanoma, wide local excision with or without sentinel lymph node dissection may be curative at any trimester of gestation, while in advanced/metastatic setting, therapeutic strategy including immune-checkpoint or BRAF/MEK inhibitors, is more challenging, regardless of BRAF status, and should be based on an individualized decision in each case at a multidisciplinary level.
Keyphrases